1. U.S. Department of Health and Human Services, Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Guidance for Industry. Bioavailability and Bioequivalence. Studies for Orally Adminsitered Drug Products-General Considerations. 2003.
2. U.S. Department of Health and Human Services, Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Guidance for Industry. Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlations. 1997.
3. U.S. Department of Health and Human Services, Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Guidance for Industry. Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. 2000.
4. National Institute of Health Sciences, Japan. Guideline for Bioequivalence Studies for Generic Products. 22 Dec 1997.
5. Committee for Medicinal Products for Human Use (CHMP). Guideline on the Investigation of Bioequivalence. 20 Jan 2010. London, European Medicines Agency (EMA).